Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163910 | 0.92 | ALDH1A1 (0.51) | NPSR1GLATHRBSMN1; SMN2LMNA | |
| SCHEMBL5859999 | 0.92 | NPSR1 (0.47) | NPSR1GLATHRBSMN1; SMN2LMNA | |
| SCHEMBL5859987 | 0.92 | NPSR1 (0.47) | NPSR1GLATHRBSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL5859992 | 0.91 | ALDH1A1 (0.50) | NPSR1GLATHRBSMN1; SMN2LMNA | |
| SCHEMBL12104073 | 0.90 | NPSR1 (0.45) | NPSR1GLATHRBSMN1; SMN2LMNA | |
| SCHEMBL5608439 | 0.88 | ALDH1A1 (0.56) | NPSR1GLASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1578928 | 0.88 | POLB (0.46) | NPSR1GLATHRBALDH1A1TSHR | |
| SCHEMBL4524325 | 0.88 | LMNA (0.49) | NPSR1GLATHRBLMNAMEN1 | |
| SCHEMBL1089145 | 0.88 | TSHR (0.47) | NPSR1GLATHRBMEN1KMT2A | |
| SCHEMBL5608918 | 0.88 | NPSR1 (0.51) | NPSR1GLATHRBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066288-A1 | DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME | PAWAR RUPA SACHIN (IN) | 2025-02-27 | — | — | US | claimed |
| CN-118666689-A | Preparation method of 1, 3-adamantane diamine | 浙江荣耀生物科技股份有限公司 | 2024-09-20 | — | — | CN | claimed |
| WO-2023237924-A1 | DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME | PAWAR RUPA SACHIN (IN) | 2023-12-14 | — | — | WO | claimed |
| CN-117210976-A | High-whiteness viscose fiber spinning oil and preparation method thereof | 乌鲁木齐市华泰隆化学助剂有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-20250277204-A1 | INSECT-DERIVED ASPARTATE DECARBOXYLASES AND VARIANTS THEREOF FOR IMPROVED BETA-ALANINE PRODUCTION | MOJIA BIOTECH LTD. (CN) | 2025-09-04 | — | — | US | disclosed |
| US-20250066288-A1 | DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME | PAWAR RUPA SACHIN (IN) | 2025-02-27 | — | — | US | disclosed |
| CN-118666689-A | Preparation method of 1, 3-adamantane diamine | 浙江荣耀生物科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118530979-A | Insect-derived aspartate decarboxylase and variants thereof for improving beta-alanine production | 广安摩珈生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115261364-B | Insect-derived aspartate decarboxylase and variants thereof for improving beta-alanine production | 广安摩珈生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4303277-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301851-A1 | INSECT-DERIVED ASPARTATE DECARBOXYLASES AND VARIANTS THEREOF FOR IMPROVED BETA-ALANINE PRODUCTION | Mojia Biotech Ltd. (CN) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023237924-A1 | DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME | PAWAR RUPA SACHIN (IN) | 2023-12-14 | — | — | WO | disclosed |
| EP-1574495-A1 | Adamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| EP-1574494-A1 | Adamantane derivative | Daicel Chemical Industries, Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| US-20050158662-A1 | Adamantane derivatives and resin compositions using the same as raw material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-07-21 | — | — | US | disclosed |
| US-6468487-B1 | SUCH AS N-HYDROXYPHTHALIMIDE; DIRECTLY AND EFFICIENTLY REACTING ADAMANTANE WITH NITROGEN OXIDE OR WITH CARBON MONOXIDE AND OXYGEN | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6392104-B1 | CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| JP-2001354618-A | METHOD FOR PRODUCING DI-TERT-BUTYL 1, 3- ADAMANTANEDICARBOXYLATE | IDEMITSU PETROCHEM CO LTD | 2001-12-25 | — | — | JP | disclosed |
| EP-0927711-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM | Daicel Chemical Industries, Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0897747-A1 | NITRATION OR CARBOXYLATION CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066288-A1 | DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME | DHODH, TALDO1, SLC5A1 | NPSR1 2114/4885GLA 590/4885THRB 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.